Category Archives: Post-grant opposition

Working to Lower Drug Costs by Challenging Questionable Patents

Posted on December 2, 2015 by donttradeourlivesaway

The New York Times, November 27, 2015. J. Kyle Bass made a fortune in the financial crisis when his hedge fund,Hayman Capital Management, bet big against subprime mortgages. Now Mr. Bass is wagering against pharmaceutical companies that he says exploit … Continue reading →

Posted in Anti competition, Evergreening, Post-grant opposition | Leave a comment

Petition to the Malaysian Minister of Health: Make Sofosbuvir available, fix patent laws!

Posted on October 13, 2015 by donttradeourlivesaway

Hepatitis C patients in Malaysia urgently need access to affordable Sofosbuvir. Help them by signing this petition to the Health Minister of Malaysia in the run-up to the International Harm Reduction Conference in Kuala Lumpur.

Posted in Compulsory Licensing, Evergreening, Hepatitis C, IPR policy, Patent Term Extension, Petitions, Post-grant opposition, Pre-grant opposition, Sofosbuvir, US - Malaysia FTA | Leave a comment

PLHIVs in Argentina file patent opposition against Gilead/BMS ARV combination Atripla

Posted on December 8, 2013 by donttradeourlivesaway

  Argentina, December 4 , 2013.- For the first time in Argentina organized communities filed a pre-grant opposition against a patent for a combination of antiretrovirals with priority use in the country. A pricing study conducted by RedLAM “Latin American … Continue reading →

Posted in Compulsory Licensing, Evergreening, Generics, Hepatitis C, HIV/Aids, IP Rights, IPR Enforcement, Patent examination system, Patents, Post-grant opposition, Pricing, Tuberculosis (TB) | Tagged , , | Leave a comment

Press Release: Trade and Industry’s draft IP policy lays foundation to prevent abusive patents from blocking access to affordable medicines

Posted on September 10, 2013 by donttradeourlivesaway

Health groups call for wide public consultation Johannesburg, 9 September – The Treatment Action Campaign (TAC), Doctors Without Borders (MSF) and SECTION27 welcome the announcement that the Department of Trade and Industry (DTI) has called for public comment on the … Continue reading →

Posted in BRICS, Compulsory Licensing, Generics, IP Rights, Post-grant opposition, Pre-grant opposition, Pricing, Right to Health, TRIPS, WHO, WTO | Tagged , , | Leave a comment

Why South Africa should Examine Pharmaceutical Patents

Posted on January 10, 2013 by donttradeourlivesaway

Treatment Action Campaign is running a campaign FIX THE PATENT LAWS in South Africa demanding for amendment of South Africa’s Patents Act 57 of 1978 to ensure access to affordable medicines, improve the health and save the lives of millions … Continue reading →

Posted in Patent examination system, Patent Opposition, Post-grant opposition, TRIPS flexibilities | Tagged , | Leave a comment

Merck’s frivolous patent on asthma inhaler revoked

Posted on December 12, 2012 by donttradeourlivesaway

On 10 December, Schering Corporation’s (now Merck) patent on an asthma inhaler has been revoked. In 2004, Schering Corporation filed an application (402/CHENP/2004) in India claiming a product patent on an aerosol suspension formulation containing two active drugs mometasone furoate and formoterol fumarate. These drugs … Continue reading →

Posted in Indian Patent Law, Patent Opposition, Post-grant opposition | Tagged , , | Leave a comment